Scopolamine Transdermal Therapeutic System (TTS) users exhibited slightly more visual problems and the agent tended to be less effective. Equally, there was no significant difference in the incidence and characteristics of adverse events reported in the various medication groups. In each active treatment group, 4.1-10.2% experienced vomiting and 16.4-23.5% experienced malaise (not significant). Follow up was possible in 1489 volunteers (85.5%). The main outcome measures were vomiting, malaise (modified Graybiel criteria), and subjective reports of adverse events. Subjects were 1741 tourist volunteers who were joining a whale safari. INTRODUCTION Motion sickness is a syndrome that occurs in response to real or perceived motion, which can include gastrointestinal, central nervous system, and autonomic symptoms. The setting was in Andenes (Norway) during a time period from July to September 1992.

On ethical grounds, a placebo group was not included as in a previous study, in the same setting, 80% of the passengers not receiving prophylactic drugs were seasick. The design was a randomized, double-blind study with two arms. The objective of the study was to compare the efficacy and tolerability of seven drugs frequently used for the prevention of seasickness: the drugs were namely cinnarizine, cinnarizine with domperidone, cyclizine, dimenhydrinate with caffeine, ginger root, meclozine with caffeine, and scopolamine. Benadryl is often taken for allergy symptoms such as runny nose and itchy eyes, and Dramamine is commonly taken for motion sickness and nausea.

Seasickness medication